ACI-002c: Thrombospondin-I antiangiogenic therapy in cats: Prospective case series in cats with measurable malignant cancers
21 May 2009
No Comment
Summary: This prospective study evaluated the effects of thrombospondin-1 peptides in 10 feline patients with various cancers. No objective response was seen in these patients. No adverse effects were noted.
Pet owners seeking novel treatment options for animals with serious health conditions find an Animal Clinical Investigation network veterinarian participating in a clinical trial.
Animal Clinical Investigation network veterinarian and pet owner work together to determine whether the pet is eligible for the trial. Eligible pets begin treatment at an ACI network hospital.
Information from the trial is used to help develop new drugs and treatments, providing a source of hope for people whose pets face serious illnesses.